Evaluation of Risk of Bullous Pemphigoid With Initiation of Dipeptidyl Peptidase-4 Inhibitor vs Second-generation Sulfonylurea.

JAMA Dermatology
Hemin LeeDae Hyun Kim

Abstract

Despite several recent reports on the elevated risk of bullous pemphigoid in patients with type 2 diabetes treated with dipeptidyl peptidase-4 (DPP-4) inhibitors, evidence on the absolute risk and comparative safety against other antidiabetics is limited. To characterize the incidence rate of bullous pemphigoid associated with DPP-4 inhibitor use compared with second-generation sulfonylureas. This cohort study used data from 2 large commercial insurance claims databases (Optum Clinformatics Data Mart from October 17, 2006, to December 31, 2018, and IBM MarketScan Research Database from October 17, 2006, to December 31, 2017) and Medicare data from January 1, 2006, to December 31, 2016. Patients with type 2 diabetes who initiated treatment with DPP-4 inhibitors or second-generation sulfonylurea were included. The primary outcome of the study was bullous pemphigoid, identified using diagnosis codes. After 1:1 propensity score matching, the incidence rates of bullous pemphigoid and the hazard ratios (HRs) with 95% CIs comparing patients who initiated DPP-4 inhibitor and second-generation sulfonylurea therapy were estimated. Subgroup analyses by age, sex, race, and individual DPP-4 agents were performed. The results from each datab...Continue Reading

References

Jul 9, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Ulf ForssmannStephan von Hörsten
Oct 20, 2009·Trends in Pharmacological Sciences·Roger YazbeckCatherine A Abbott
Jul 14, 2010·Archives of Internal Medicine·Shrey DesaiSolomon Iyasu
Aug 4, 2010·Pharmacoepidemiology and Drug Safety·Sebastian Schneeweiss
Apr 7, 2011·Journal of the European Academy of Dermatology and Venereology : JEADV·K SkandalisI D Bassukas
Nov 23, 2012·Diabetes Care·Samy Suissa, Laurent Azoulay
Dec 15, 2012·Lancet·Enno Schmidt, Detlef Zillikens
Mar 25, 2015·Nature Reviews. Rheumatology·Kazuki YoshidaSeoyoung C Kim
Sep 20, 2015·The British Journal of Dermatology·D HsuJ I Silverberg
Feb 14, 2016·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Annamaria MascoloAnnalisa Capuano
Apr 1, 2016·The British Journal of Dermatology·J BénéUNKNOWN French Association of Regional PharmacoVigilance Centres
Oct 25, 2016·The Journal of Investigative Dermatology·Kentaro IzumiHiroshi Shimizu
Aug 18, 2016·European Heart Journal. Cardiovascular Pharmacotherapy·Friederike RemmChristoph Brenner
Jan 22, 2017·Diabetes Care·J Hans DeVries, Julio Rosenstock
Sep 7, 2017·Archives of Dermatological Research·Kristofer ThorslundCarina Grönhagen
Oct 19, 2017·Dermatology : International Journal for Clinical and Investigative Dermatology·Clara SchafferLaurence Feldmeyer
Feb 11, 2018·The Journal of Investigative Dermatology·Outi VarpuluomaKaisa Tasanen
Nov 13, 2018·JAMA : the Journal of the American Medical Association·Julio RosenstockUNKNOWN CARMELINA Investigators
Dec 14, 2018·The Journal of Investigative Dermatology·Marthe PlaqueventUNKNOWN French Study Group on Autoimmune Bullous Skin Diseases
Jul 6, 2019·Frontiers in Immunology·Kaisa TasanenWataru Nishie

❮ Previous
Next ❯

Citations

Nov 2, 2020·Experimental Dermatology·Payal M PatelKyle T Amber
Apr 8, 2021·Expert Opinion on Pharmacotherapy·André J Scheen
May 25, 2021·Experimental Dermatology·Lula María Nieto-BenitoRicardo Suárez-Fernández
Jun 12, 2021·The Journal of Investigative Dermatology·Outi VarpuluomaKaisa Tasanen

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Medicina clínica
Rubén García CastroConcepción Román Curto
European Journal of Case Reports in Internal Medicine
Ali SomeiliMohannad Abu Hilal
© 2021 Meta ULC. All rights reserved